Generic Name:
brentuximab vedotin
Project Status:
Pending
Therapeutic Area:
Hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine
Manufacturer:
Seagen Canada Inc.
Call for patient/clinician input open:
Brand Name:
Adcetris
Project Line:
Reimbursement Review
Project Number:
PC0311-000
Call for patient/clinician input closed:
Tumour Type:
Lymphoma
Details
Manufacturer Requested Reimbursement Criteria1:
For the treatment of previously untreated patients with advanced stage HL, in combination with doxorubicin, vinblastine, and dacarbazine.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Adcetris (brentuximab vedotin for injection) is indicated for the treatment of previously untreated patients with advanced stage Hodgkin lymphoma (HL), in combination with doxorubicin, vinblastine, and dacarbazine.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.